Global Patent Index - EP 2263090 A1

EP 2263090 A1 20101222 - ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB)

Title (en)

ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB)

Title (de)

MORBUS-ALZHEIMER-SPEZIFISCHE VERÄNDERUNGEN DES ERK1/ERK2-PHOSPHORYLIERUNGSVERHÄLTNISSES ALS MORBUS-ALZHEIMER-SPEZIFISCHE MOLEKULARE BIOMARKER

Title (fr)

MODIFICATIONS SPÉCIFIQUES DE LA MALADIE D'ALZHEIMER DU RAPPORT DE PHOSPHORYLATION D ERK1/ERK2, BIOMARQUEURS MOLÉCULAIRES SPÉCIFIQUES DE LA MALADIE D ALZHEIMER (ADSMB)

Publication

EP 2263090 A1 20101222 (EN)

Application

EP 09731007 A 20090403

Priority

  • US 2009002120 W 20090403
  • US 7885708 A 20080407

Abstract (en)

[origin: WO2009126232A1] The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's Disease- specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's Disease, monitoring the progression of Alzheimer's Disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's Disease. The invention is also directed to kits containing reagents for the detection and diagnosis of the presence or absence of Alzheimer's Disease using the Alzheimer's Disease-specific molecular biomarkers disclosed herein.

IPC 8 full level

G01N 33/68 (2006.01)

CPC (source: EP)

A61P 25/28 (2017.12); G01N 33/6896 (2013.01); G01N 2800/2821 (2013.01); G01N 2800/52 (2013.01)

Citation (search report)

See references of WO 2009126232A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA RS

DOCDB simple family (publication)

WO 2009126232 A1 20091015; AU 2009234405 A1 20091015; BR PI0911073 A2 20190924; CA 2720621 A1 20091015; EP 2263090 A1 20101222; IL 208296 A0 20101230; JP 2011516883 A 20110526; KR 20100132997 A 20101220; TW 200942819 A 20091016

DOCDB simple family (application)

US 2009002120 W 20090403; AU 2009234405 A 20090403; BR PI0911073 A 20090403; CA 2720621 A 20090403; EP 09731007 A 20090403; IL 20829610 A 20100921; JP 2011503976 A 20090403; KR 20107024733 A 20090403; TW 98108600 A 20090317